September 7, 2026
September 29 is the second and final cliff for importers outside the MFN framework, and Q4 guidance season will force the reckoning into plain sight.
The first Section 232 tariff deadline passed on July 31 for the 17 largest drugmakers named in Annex III. Most of them spent the preceding months cutting pricing deals to get the rate to zero. The market noticed, exhaled, and largely moved on. That was a mistake, because a second, broader deadline is now 22 days away.
Your Power Bill Is Funding the AI Boom
The bulk order that keeps the lights on across 13 states just jumped from $2.2 billion to $14.7 billion – nearly 7x in one year – because data centers are draining the grid. There’s one energy source that runs 24/7 with no fuel, and Washington just preserved its tax credits through 2033 while terminating everyone else’s. Google signed for 15 years. Bill Gates invested $100 million. One company has spent sixty years building it.
Companies not listed in Annex III of Proclamation 11020 face a 100% tariff on patented pharmaceuticals and associated pharmaceutical ingredients, effective September 29, 2026. Approved onshoring agreements cut the duty to 20%, while MFN pricing agreements push it all the way to zero through January 20, 2029. Generics and biosimilars sit outside the patented-drug tariff lane described in the proclamation, alongside other carve-outs listed in the annexes. The September 29 wave touches a far wider universe of smaller and mid-tier branded importers who never made the Annex III list in the first place.
Who Already Locked In Relief
As of August 31, the White House says the Administration has agreements with Pfizer, AstraZeneca, Novo Nordisk, GSK, Sanofi, Johnson & Johnson, and 19 other companies, with Teva among the most recently added signatories. For those names, the tariff math is largely settled: companies that enter into approved onshoring agreements with BIS receive a reduced duty rate of 20%, and those that also enter into MFN pricing agreements with HHS receive a 0% duty rate through January 20, 2029.
GSK’s situation illustrates how the framework plays out operationally. GSK entered into an agreement with the U.S. Administration on December 19, 2025, and on April 9, 2026, GSK, ViiV Healthcare, and the U.S. Government entered into a definitive agreement reflecting Section 232 tariff relief through January 20, 2029. GSK says its full-year guidance is inclusive of the expected impact of these agreements. That last line is the key one for options traders: guidance that already bakes in tariff resolution is guidance that doesn’t need to be revised downward.
5 Nasdaq Stocks Under $5 That Aren’t What You Think
Most stocks under $5 come with a reputation. These don’t.
Each company on this list is tied to major trends like AI, cybersecurity, and next-gen infrastructure.
They may not have the spotlight yet, but they are building real businesses in real markets. That combination is not always easy to find at this price level.
Where the Options Opportunity Lives
The more interesting question is not who secured relief, it is who has not, and whether the market has fully priced in the Q4 guidance revisions those companies will be forced to make. Exiger has said that despite recent volatility, a significant volume of branded pharmaceutical shipments remain exposed to 100% tariffs effective September 29, and its analysis of patented pharmaceutical and branded API shipment records points to U.S. supply chain exposure beyond the 17 companies identified in Annex III, including branded shipments from manufacturers not captured in that list that remain fully exposed.
The options angle is specific: when companies report Q3 results in October and November, any importer still absorbing the 100% rate must quantify the cost in their Q4 outlook. That disclosure event is the catalyst. The implied volatility across large-cap pharma remains relatively subdued heading into a three-week window that carries a concrete cost shock for a subset of the space, and that gap between realized risk and priced risk is where defined-risk strategies earn their keep.
The Trade Structure
A bear put spread on a name with confirmed, unresolved tariff exposure and a Q3 earnings call in October offers a defined-risk way to position for a guidance cut. Buy an at-the-money October or November put, sell a lower-strike put four to six points out to offset premium decay. The spread caps total loss at the net debit, keeps the risk-reward ratio above 2:1 on the right name, and expires after the earnings disclosure window closes.
The thesis does not require the stock to collapse. It requires management to acknowledge, on a live call, that 100% import duties are now a line item in Q4 cost of goods. That acknowledgment alone tends to move the stock more than investors expect, because the sell-side models built before April 2 do not yet reflect it.
Inside the Nuclear Revival Reshaping Energy Markets
Governments worldwide are investing billions to revive a proven energy source. Supply chains are tightening, demand is rising, and select companies stand to benefit. The Nuclear’s Second Act report explains what’s happening next.
What Would Kill the Trade
A last-minute onshoring agreement or MFN deal announced before September 29 removes the tariff headwind for that specific company and turns the put spread into a loss. Industry coverage of the second round of MFN agreements noted that while the White House release did not explicitly reference tariffs, the pressure of trade duties has been ever-present in the deals struck so far, with companies from Pfizer and AstraZeneca to Roche, Novartis, and Johnson & Johnson making drug pricing commitments and domestic investment pledges to win temporary immunity from import tariffs. A company willing to make that trade can exit this risk quickly.
Position size matters. A spread that risks 1-2% of capital on a high-conviction thesis is disciplined. Betting on a single name without confirming its tariff exposure via SEC filings and import data is not.
The Beast Verdict
September 29 is a hard date written into a White House proclamation. It is not a rumor or an analyst estimate. Companies still absorbing the 100% rate will have to say so on their Q3 earnings calls, and options markets are not yet pricing that disclosure as the event it is. The opportunity is not in the Annex III names that settled months ago. It is in the second tier: branded importers who ran out the clock, now facing a cost structure that forces a conversation with shareholders they have not yet had.
